Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne.

ABSTRACT:

Background

Treatment for both facial and truncal acne has not sufficiently been studied.

Objectives

To evaluate the long-term safety and efficacy of trifarotene in both facial and truncal acne.

Methods

In a multicentre, open-label, 52-week study, patients with moderate facial and truncal acne received trifarotene 50 μg/g cream (trifarotene). Assessments included local tolerability, safety, investigator and physician's global assessments (IGA, PGA) and quality of life (QOL). A validated QOL questionnaire was completed by the patient at Baseline, Week 12, 26 and 52/ET.

Results

Of 453 patients enrolled, 342 (75.5%) completed the study. Trifarotene-related treatment-emergent adverse events (TEAEs) were reported in 12.6% of patients, and none was serious. Most relat

SUBMITTER: Blume-Peytavi U 

PROVIDER: S-EPMC7004112 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature